Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foscenvivint - PRISM Pharma Co

Drug Profile

Foscenvivint - PRISM Pharma Co

Alternative Names: CBP-beta catenin inhibitor; ICG-001; OP-724; PRI-724

Latest Information Update: 30 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PRISM BioLab; University of Southern California
  • Developer Ohara Pharmaceutical; PRISM Pharma Co; Syneos Health; Tokyo Metropolitan Komagome Hospital
  • Class Antifibrotics; Antineoplastics; Pyrazines; Quinolines; Small molecules; Triazines
  • Mechanism of Action Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cirrhosis
  • Phase I Primary biliary cirrhosis
  • Preclinical Prostate cancer
  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Hepatic fibrosis; Pancreatic cancer; Solid tumours

Most Recent Events

  • 08 Apr 2022 Preclinical trials in Prostate cancer in Japan (unspecified route)
  • 08 Apr 2022 Pharmacodynamics data from a preclinical in prostate cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 31 Mar 2022 OHARA Pharmaceuticals completes phase I trial in Primary biliary cirrhosis in Japan (IV) (NCT04047160)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top